Ortin Global Limited (ORTINGLOBE) - Net Assets
Based on the latest financial reports, Ortin Global Limited (ORTINGLOBE) has net assets worth Rs13.00 Million INR (≈ $140.55K USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs38.26 Million ≈ $413.77K USD) and total liabilities (Rs25.26 Million ≈ $273.22K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ORTINGLOBE cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs13.00 Million |
| % of Total Assets | 33.97% |
| Annual Growth Rate | -35.4% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 29.39 |
Ortin Global Limited - Net Assets Trend (2021–2025)
This chart illustrates how Ortin Global Limited's net assets have evolved over time, based on quarterly financial data. Also explore ORTINGLOBE current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Ortin Global Limited (2021–2025)
The table below shows the annual net assets of Ortin Global Limited from 2021 to 2025. For live valuation and market cap data, see how much is Ortin Global Limited worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs19.77 Million ≈ $213.86K |
-29.97% |
| 2024-03-31 | Rs28.24 Million ≈ $305.39K |
-74.01% |
| 2023-03-31 | Rs108.65 Million ≈ $1.17 Million |
-0.84% |
| 2022-03-31 | Rs109.57 Million ≈ $1.18 Million |
-3.51% |
| 2021-03-31 | Rs113.56 Million ≈ $1.23 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Ortin Global Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 363.7% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Rs81.31 Million | 411.20% |
| Other Components | Rs6.45 Million | 32.63% |
| Total Equity | Rs19.77 Million | 100.00% |
Ortin Global Limited Competitors by Market Cap
The table below lists competitors of Ortin Global Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Luminar Technologies Inc. Class A
NASDAQ:LAZRQ
|
$1.36 Million |
|
Smartfren Telecom Tbk
JK:FREN
|
$1.36 Million |
|
Elbit Med Tech
TA:EMTC
|
$1.36 Million |
|
VULTUS AB
F:V06
|
$1.37 Million |
|
Fuse Cobalt Inc
V:FUSE
|
$1.36 Million |
|
GS TECHS LTD (DI)
F:6Y3
|
$1.36 Million |
|
DevvStream Corp. Common Stock
NASDAQ:DEVS
|
$1.36 Million |
|
Europa Metals Ltd
JSE:EUZ
|
$1.36 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ortin Global Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 28,239,000 to 19,775,000, a change of -8,464,000 (-30.0%).
- Net loss of 8,464,000 reduced equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs-8.46 Million | -42.8% |
| Total Change | Rs- | -29.97% |
Book Value vs Market Value Analysis
This analysis compares Ortin Global Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.37x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 1.11x to 6.37x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-03-31 | Rs13.97 | Rs15.50 | x |
| 2022-03-31 | Rs13.47 | Rs15.50 | x |
| 2023-03-31 | Rs13.36 | Rs15.50 | x |
| 2024-03-31 | Rs3.47 | Rs15.50 | x |
| 2025-03-31 | Rs2.43 | Rs15.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ortin Global Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -42.80%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -247.34%
- • Asset Turnover: 0.09x
- • Equity Multiplier: 1.91x
- Recent ROE (-42.80%) is above the historical average (-64.74%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 8.33% | 11.58% | 0.38x | 1.87x | Rs-1.90 Million |
| 2022 | -3.64% | -4.84% | 0.40x | 1.89x | Rs-14.94 Million |
| 2023 | -0.86% | -1.55% | 0.28x | 1.95x | Rs-11.80 Million |
| 2024 | -284.75% | -380.82% | 0.32x | 2.36x | Rs-83.23 Million |
| 2025 | -42.80% | -247.34% | 0.09x | 1.91x | Rs-10.44 Million |
Industry Comparison
This section compares Ortin Global Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $23,713,303,062
- Average return on equity (ROE) among peers: 8.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ortin Global Limited (ORTINGLOBE) | Rs13.00 Million | 8.33% | 1.94x | $1.36 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $988.60 Million | 6.59% | 1.36x | $27.93 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $6.52 Billion | 21.67% | 1.42x | $371.43 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $19.90 Billion | 13.69% | 0.46x | $725.68 Million |
| Abbott India Limited (ABBOTINDIA) | $36.99 Billion | 32.48% | 0.40x | $5.85 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $1.16 Billion | 12.69% | 1.32x | $3.81 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $6.25 Billion | -40.39% | 3.91x | $906.19 Million |
| Alkem Laboratories Limited (ALKEM) | $88.47 Billion | 18.60% | 0.59x | $6.98 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $1.46 Billion | 16.82% | 0.29x | $178.52 Million |
| Alembic Pharmaceuticals Limited (APLLTD) | $51.90 Billion | 11.24% | 0.50x | $1.60 Billion |
| Aurobindo Pharma Limited (AUROPHARMA) | $23.50 Billion | -5.26% | 1.65x | $8.73 Billion |
About Ortin Global Limited
Ortin Global Limited engages in the manufacture and trading of pharmaceuticals, drugs, and intermediates in India. The company offers various pharmaceutical formulations of tablets, capsules, syrups, and dry powders; formulations, such as anti-diabetics, anti-allergics, anti-anginal and cardiovascular, sedatives and tranquilisers, anti-helmenthetics, analgesics and antipyretics, anti-biotics-quin… Read more